Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
J Dermatol ; 49(6): 652-655, 2022 Jun.
Article in English | MEDLINE | ID: covidwho-1731048

ABSTRACT

Drug-induced hypersensitivity syndrome (DiHS) is a severe drug eruption that can induce reactivation of herpesviruses such as human herpesvirus 6, resulting in symptom flare-up and organ damage. DiHS is known as drug reaction with eosinophilia and systemic symptoms (DRESS) in Europe. We report three cases of DiHS that could have been triggered by mRNA-based coronavirus disease 2019 (COVID-19) vaccines. In these three patients, symptoms of DiHS developed 2-6 days after the first dose of an mRNA-based COVID-19 vaccine. Although there have been no reports of DiHS/DRESS induced by mRNA-based COVID-19 vaccines in domestic and international journals despite the progress in vaccination worldwide, we speculate that mRNA-based COVID-19 vaccines might have triggered the development of DiHS/DRESS in our patients. In the current coronavirus epidemic, it might be important to assess mRNA-based COVID-19 vaccination status and date of vaccination when evaluating a patient with DiHS/DRESS.


Subject(s)
COVID-19 , Drug Hypersensitivity Syndrome , Drug Hypersensitivity , Eosinophilia , COVID-19/prevention & control , COVID-19 Vaccines/adverse effects , Drug Hypersensitivity Syndrome/complications , Drug Hypersensitivity Syndrome/etiology , Eosinophilia/complications , Humans , RNA, Messenger
SELECTION OF CITATIONS
SEARCH DETAIL